cd138 cells Search Results


cd138 isolation kit  (Miltenyi Biotec)
94
Miltenyi Biotec cd138 isolation kit
Cd138 Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138 isolation kit/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd138 isolation kit - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
human sdc1  (Sino Biological)
93
Sino Biological human sdc1
Syndecans (SDCs) enhance ghrelin-stimulated growth hormone secretagogue receptor (GHSR) signaling. (A) Time course of aequorin luminescence after ghrelin treatment in cells expressing GHSR with control or <t>SDC1</t> expression plasmids at 1:20 ratio. (B) Comparison of peak iCa 2+ responses derived from curve-fitting data from A (* P < 0.05, GHSR alone versus SDC1 co-transfection). (C) Dose–response curves of intracellular ghrelin-stimulated iCa 2+ expressed as % Emax of 1:0 ratio: effect of different GHSR:SDC1 transfection ratios (* P < 0.05, *** P < 0.0005, Emax for GHSR:SDC co-expression versus GHSR alone (GHSR:SDC, 1:0) tested by ANOVA). (D) EC 50 s for ghrelin derived from dose–response curves shown in (C) (SDC1 ratios). (E) Effect of all SDCs co-transfected at a GHSR:SDC ratio of 1:20 (** P < 0.005 (t-test), Emax for GHSR:SDC co-expression versus GHSR alone). (F) Effect of all SDCs co-transfected at a GHSR:SDC ratio of 1:1 (* P ≤ 0.05 (t-test), Emax for GHSR:SDC co-expression versus GHSR alone). (G) EC 50 s for ghrelin derived from SDC1–SDC4 dose–response curves shown in (E) and (F). (H) and (I) Dose–response curves of IP1 accumulation after ghrelin stimulation of cells expressing GHSR in the presence or absence of SDC1 at 1:20 and 1:1 ratios, respectively, corrected for baseline (* P ≤ 0.05 (t-test), Emax ghrelin-induced IP1 levels of 1:0 v. 1:20 or 1:1 ratio). (J) and (K) Dose–response curves of IP1 levels after ghrelin stimulation of cells expressing GHSR in the presence or absence of SDC1 at 1:20 and 1:1 ratios, respectively, expressed as % of maximum response in the absence of SDC1 (* P ≤ 0.05, ** P < 0.01 (t-test), basal IP1 levels of 1:0 v. 1:20 or 1:1 ratio, respectively). Data are mean ± SEM of three or more independent experiments.
Human Sdc1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human sdc1/product/Sino Biological
Average 93 stars, based on 1 article reviews
human sdc1 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
cd138/syndecan-1 mouse monoclonal antibody  (Cell Marque)
90
Cell Marque cd138/syndecan-1 mouse monoclonal antibody
Syndecans (SDCs) enhance ghrelin-stimulated growth hormone secretagogue receptor (GHSR) signaling. (A) Time course of aequorin luminescence after ghrelin treatment in cells expressing GHSR with control or <t>SDC1</t> expression plasmids at 1:20 ratio. (B) Comparison of peak iCa 2+ responses derived from curve-fitting data from A (* P < 0.05, GHSR alone versus SDC1 co-transfection). (C) Dose–response curves of intracellular ghrelin-stimulated iCa 2+ expressed as % Emax of 1:0 ratio: effect of different GHSR:SDC1 transfection ratios (* P < 0.05, *** P < 0.0005, Emax for GHSR:SDC co-expression versus GHSR alone (GHSR:SDC, 1:0) tested by ANOVA). (D) EC 50 s for ghrelin derived from dose–response curves shown in (C) (SDC1 ratios). (E) Effect of all SDCs co-transfected at a GHSR:SDC ratio of 1:20 (** P < 0.005 (t-test), Emax for GHSR:SDC co-expression versus GHSR alone). (F) Effect of all SDCs co-transfected at a GHSR:SDC ratio of 1:1 (* P ≤ 0.05 (t-test), Emax for GHSR:SDC co-expression versus GHSR alone). (G) EC 50 s for ghrelin derived from SDC1–SDC4 dose–response curves shown in (E) and (F). (H) and (I) Dose–response curves of IP1 accumulation after ghrelin stimulation of cells expressing GHSR in the presence or absence of SDC1 at 1:20 and 1:1 ratios, respectively, corrected for baseline (* P ≤ 0.05 (t-test), Emax ghrelin-induced IP1 levels of 1:0 v. 1:20 or 1:1 ratio). (J) and (K) Dose–response curves of IP1 levels after ghrelin stimulation of cells expressing GHSR in the presence or absence of SDC1 at 1:20 and 1:1 ratios, respectively, expressed as % of maximum response in the absence of SDC1 (* P ≤ 0.05, ** P < 0.01 (t-test), basal IP1 levels of 1:0 v. 1:20 or 1:1 ratio, respectively). Data are mean ± SEM of three or more independent experiments.
Cd138/Syndecan 1 Mouse Monoclonal Antibody, supplied by Cell Marque, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138/syndecan-1 mouse monoclonal antibody/product/Cell Marque
Average 90 stars, based on 1 article reviews
cd138/syndecan-1 mouse monoclonal antibody - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd138-positive snap-frozen plasma cell pellets  (AllCells LLC)
90
AllCells LLC cd138-positive snap-frozen plasma cell pellets
Syndecans (SDCs) enhance ghrelin-stimulated growth hormone secretagogue receptor (GHSR) signaling. (A) Time course of aequorin luminescence after ghrelin treatment in cells expressing GHSR with control or <t>SDC1</t> expression plasmids at 1:20 ratio. (B) Comparison of peak iCa 2+ responses derived from curve-fitting data from A (* P < 0.05, GHSR alone versus SDC1 co-transfection). (C) Dose–response curves of intracellular ghrelin-stimulated iCa 2+ expressed as % Emax of 1:0 ratio: effect of different GHSR:SDC1 transfection ratios (* P < 0.05, *** P < 0.0005, Emax for GHSR:SDC co-expression versus GHSR alone (GHSR:SDC, 1:0) tested by ANOVA). (D) EC 50 s for ghrelin derived from dose–response curves shown in (C) (SDC1 ratios). (E) Effect of all SDCs co-transfected at a GHSR:SDC ratio of 1:20 (** P < 0.005 (t-test), Emax for GHSR:SDC co-expression versus GHSR alone). (F) Effect of all SDCs co-transfected at a GHSR:SDC ratio of 1:1 (* P ≤ 0.05 (t-test), Emax for GHSR:SDC co-expression versus GHSR alone). (G) EC 50 s for ghrelin derived from SDC1–SDC4 dose–response curves shown in (E) and (F). (H) and (I) Dose–response curves of IP1 accumulation after ghrelin stimulation of cells expressing GHSR in the presence or absence of SDC1 at 1:20 and 1:1 ratios, respectively, corrected for baseline (* P ≤ 0.05 (t-test), Emax ghrelin-induced IP1 levels of 1:0 v. 1:20 or 1:1 ratio). (J) and (K) Dose–response curves of IP1 levels after ghrelin stimulation of cells expressing GHSR in the presence or absence of SDC1 at 1:20 and 1:1 ratios, respectively, expressed as % of maximum response in the absence of SDC1 (* P ≤ 0.05, ** P < 0.01 (t-test), basal IP1 levels of 1:0 v. 1:20 or 1:1 ratio, respectively). Data are mean ± SEM of three or more independent experiments.
Cd138 Positive Snap Frozen Plasma Cell Pellets, supplied by AllCells LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138-positive snap-frozen plasma cell pellets/product/AllCells LLC
Average 90 stars, based on 1 article reviews
cd138-positive snap-frozen plasma cell pellets - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd138 + bm cells  (ProteoGenex Inc)
90
ProteoGenex Inc cd138 + bm cells
Teclistamab-induced cytotoxicity and activation of MM BM MNC cells ex vivo. Each row represents a different patient sample. Frozen BM MNCs were incubated with various concentrations of teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target binding and killing. BCMA protein density was 2451 receptors per plasma cell in one of the patient samples (ID BM 240 MM). (A) Dose-dependent binding of teclistamab to target cells. (B) Dose-dependent plasma cell depletion. BM MNCs were incubated for 48 hours with exogenous healthy T cells at a 1:1 E:T ratio in the presence of teclistamab and depletion measured as remaining <t>CD138+</t> cells. (C) Teclistamab-mediated T-cell activation was measured via flow cytometry by gating T cells using CD3 surface marker and CD25 activation marker. Percent CD25+ T cell values were plotted on the y-axis. Teclistamab was able to activate T cells efficiently when incubated with BM MNCs, whereas the control antibodies had no effect.
Cd138 + Bm Cells, supplied by ProteoGenex Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138 + bm cells/product/ProteoGenex Inc
Average 90 stars, based on 1 article reviews
cd138 + bm cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd138+ cell enrichment of bma  (LabCorp)
90
LabCorp cd138+ cell enrichment of bma
Teclistamab-induced cytotoxicity and activation of MM BM MNC cells ex vivo. Each row represents a different patient sample. Frozen BM MNCs were incubated with various concentrations of teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target binding and killing. BCMA protein density was 2451 receptors per plasma cell in one of the patient samples (ID BM 240 MM). (A) Dose-dependent binding of teclistamab to target cells. (B) Dose-dependent plasma cell depletion. BM MNCs were incubated for 48 hours with exogenous healthy T cells at a 1:1 E:T ratio in the presence of teclistamab and depletion measured as remaining <t>CD138+</t> cells. (C) Teclistamab-mediated T-cell activation was measured via flow cytometry by gating T cells using CD3 surface marker and CD25 activation marker. Percent CD25+ T cell values were plotted on the y-axis. Teclistamab was able to activate T cells efficiently when incubated with BM MNCs, whereas the control antibodies had no effect.
Cd138+ Cell Enrichment Of Bma, supplied by LabCorp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138+ cell enrichment of bma/product/LabCorp
Average 90 stars, based on 1 article reviews
cd138+ cell enrichment of bma - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd138+ plasmablasts  (Verlag GmbH)
90
Verlag GmbH cd138+ plasmablasts
Teclistamab-induced cytotoxicity and activation of MM BM MNC cells ex vivo. Each row represents a different patient sample. Frozen BM MNCs were incubated with various concentrations of teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target binding and killing. BCMA protein density was 2451 receptors per plasma cell in one of the patient samples (ID BM 240 MM). (A) Dose-dependent binding of teclistamab to target cells. (B) Dose-dependent plasma cell depletion. BM MNCs were incubated for 48 hours with exogenous healthy T cells at a 1:1 E:T ratio in the presence of teclistamab and depletion measured as remaining <t>CD138+</t> cells. (C) Teclistamab-mediated T-cell activation was measured via flow cytometry by gating T cells using CD3 surface marker and CD25 activation marker. Percent CD25+ T cell values were plotted on the y-axis. Teclistamab was able to activate T cells efficiently when incubated with BM MNCs, whereas the control antibodies had no effect.
Cd138+ Plasmablasts, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138+ plasmablasts/product/Verlag GmbH
Average 90 stars, based on 1 article reviews
cd138+ plasmablasts - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd138-negative clonogenic cells  (Kishida Chemical)
90
Kishida Chemical cd138-negative clonogenic cells
Teclistamab-induced cytotoxicity and activation of MM BM MNC cells ex vivo. Each row represents a different patient sample. Frozen BM MNCs were incubated with various concentrations of teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target binding and killing. BCMA protein density was 2451 receptors per plasma cell in one of the patient samples (ID BM 240 MM). (A) Dose-dependent binding of teclistamab to target cells. (B) Dose-dependent plasma cell depletion. BM MNCs were incubated for 48 hours with exogenous healthy T cells at a 1:1 E:T ratio in the presence of teclistamab and depletion measured as remaining <t>CD138+</t> cells. (C) Teclistamab-mediated T-cell activation was measured via flow cytometry by gating T cells using CD3 surface marker and CD25 activation marker. Percent CD25+ T cell values were plotted on the y-axis. Teclistamab was able to activate T cells efficiently when incubated with BM MNCs, whereas the control antibodies had no effect.
Cd138 Negative Clonogenic Cells, supplied by Kishida Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138-negative clonogenic cells/product/Kishida Chemical
Average 90 stars, based on 1 article reviews
cd138-negative clonogenic cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
plasma cell reactivity for the cd138  (IMI Co Ltd)
90
IMI Co Ltd plasma cell reactivity for the cd138
Teclistamab-induced cytotoxicity and activation of MM BM MNC cells ex vivo. Each row represents a different patient sample. Frozen BM MNCs were incubated with various concentrations of teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target binding and killing. BCMA protein density was 2451 receptors per plasma cell in one of the patient samples (ID BM 240 MM). (A) Dose-dependent binding of teclistamab to target cells. (B) Dose-dependent plasma cell depletion. BM MNCs were incubated for 48 hours with exogenous healthy T cells at a 1:1 E:T ratio in the presence of teclistamab and depletion measured as remaining <t>CD138+</t> cells. (C) Teclistamab-mediated T-cell activation was measured via flow cytometry by gating T cells using CD3 surface marker and CD25 activation marker. Percent CD25+ T cell values were plotted on the y-axis. Teclistamab was able to activate T cells efficiently when incubated with BM MNCs, whereas the control antibodies had no effect.
Plasma Cell Reactivity For The Cd138, supplied by IMI Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasma cell reactivity for the cd138/product/IMI Co Ltd
Average 90 stars, based on 1 article reviews
plasma cell reactivity for the cd138 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd138-negative clonogenic cells  (Hasegawa Co Ltd)
90
Hasegawa Co Ltd cd138-negative clonogenic cells
Teclistamab-induced cytotoxicity and activation of MM BM MNC cells ex vivo. Each row represents a different patient sample. Frozen BM MNCs were incubated with various concentrations of teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target binding and killing. BCMA protein density was 2451 receptors per plasma cell in one of the patient samples (ID BM 240 MM). (A) Dose-dependent binding of teclistamab to target cells. (B) Dose-dependent plasma cell depletion. BM MNCs were incubated for 48 hours with exogenous healthy T cells at a 1:1 E:T ratio in the presence of teclistamab and depletion measured as remaining <t>CD138+</t> cells. (C) Teclistamab-mediated T-cell activation was measured via flow cytometry by gating T cells using CD3 surface marker and CD25 activation marker. Percent CD25+ T cell values were plotted on the y-axis. Teclistamab was able to activate T cells efficiently when incubated with BM MNCs, whereas the control antibodies had no effect.
Cd138 Negative Clonogenic Cells, supplied by Hasegawa Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138-negative clonogenic cells/product/Hasegawa Co Ltd
Average 90 stars, based on 1 article reviews
cd138-negative clonogenic cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cell gating and lymphomonocytic populatio coexpressing cd38 and cd138  (Diagnos Inc)
90
Diagnos Inc cell gating and lymphomonocytic populatio coexpressing cd38 and cd138
Teclistamab-induced cytotoxicity and activation of MM BM MNC cells ex vivo. Each row represents a different patient sample. Frozen BM MNCs were incubated with various concentrations of teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target binding and killing. BCMA protein density was 2451 receptors per plasma cell in one of the patient samples (ID BM 240 MM). (A) Dose-dependent binding of teclistamab to target cells. (B) Dose-dependent plasma cell depletion. BM MNCs were incubated for 48 hours with exogenous healthy T cells at a 1:1 E:T ratio in the presence of teclistamab and depletion measured as remaining <t>CD138+</t> cells. (C) Teclistamab-mediated T-cell activation was measured via flow cytometry by gating T cells using CD3 surface marker and CD25 activation marker. Percent CD25+ T cell values were plotted on the y-axis. Teclistamab was able to activate T cells efficiently when incubated with BM MNCs, whereas the control antibodies had no effect.
Cell Gating And Lymphomonocytic Populatio Coexpressing Cd38 And Cd138, supplied by Diagnos Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell gating and lymphomonocytic populatio coexpressing cd38 and cd138/product/Diagnos Inc
Average 90 stars, based on 1 article reviews
cell gating and lymphomonocytic populatio coexpressing cd38 and cd138 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd138-cell fish  (Cytocell Inc)
90
Cytocell Inc cd138-cell fish
Teclistamab-induced cytotoxicity and activation of MM BM MNC cells ex vivo. Each row represents a different patient sample. Frozen BM MNCs were incubated with various concentrations of teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target binding and killing. BCMA protein density was 2451 receptors per plasma cell in one of the patient samples (ID BM 240 MM). (A) Dose-dependent binding of teclistamab to target cells. (B) Dose-dependent plasma cell depletion. BM MNCs were incubated for 48 hours with exogenous healthy T cells at a 1:1 E:T ratio in the presence of teclistamab and depletion measured as remaining <t>CD138+</t> cells. (C) Teclistamab-mediated T-cell activation was measured via flow cytometry by gating T cells using CD3 surface marker and CD25 activation marker. Percent CD25+ T cell values were plotted on the y-axis. Teclistamab was able to activate T cells efficiently when incubated with BM MNCs, whereas the control antibodies had no effect.
Cd138 Cell Fish, supplied by Cytocell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138-cell fish/product/Cytocell Inc
Average 90 stars, based on 1 article reviews
cd138-cell fish - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Syndecans (SDCs) enhance ghrelin-stimulated growth hormone secretagogue receptor (GHSR) signaling. (A) Time course of aequorin luminescence after ghrelin treatment in cells expressing GHSR with control or SDC1 expression plasmids at 1:20 ratio. (B) Comparison of peak iCa 2+ responses derived from curve-fitting data from A (* P < 0.05, GHSR alone versus SDC1 co-transfection). (C) Dose–response curves of intracellular ghrelin-stimulated iCa 2+ expressed as % Emax of 1:0 ratio: effect of different GHSR:SDC1 transfection ratios (* P < 0.05, *** P < 0.0005, Emax for GHSR:SDC co-expression versus GHSR alone (GHSR:SDC, 1:0) tested by ANOVA). (D) EC 50 s for ghrelin derived from dose–response curves shown in (C) (SDC1 ratios). (E) Effect of all SDCs co-transfected at a GHSR:SDC ratio of 1:20 (** P < 0.005 (t-test), Emax for GHSR:SDC co-expression versus GHSR alone). (F) Effect of all SDCs co-transfected at a GHSR:SDC ratio of 1:1 (* P ≤ 0.05 (t-test), Emax for GHSR:SDC co-expression versus GHSR alone). (G) EC 50 s for ghrelin derived from SDC1–SDC4 dose–response curves shown in (E) and (F). (H) and (I) Dose–response curves of IP1 accumulation after ghrelin stimulation of cells expressing GHSR in the presence or absence of SDC1 at 1:20 and 1:1 ratios, respectively, corrected for baseline (* P ≤ 0.05 (t-test), Emax ghrelin-induced IP1 levels of 1:0 v. 1:20 or 1:1 ratio). (J) and (K) Dose–response curves of IP1 levels after ghrelin stimulation of cells expressing GHSR in the presence or absence of SDC1 at 1:20 and 1:1 ratios, respectively, expressed as % of maximum response in the absence of SDC1 (* P ≤ 0.05, ** P < 0.01 (t-test), basal IP1 levels of 1:0 v. 1:20 or 1:1 ratio, respectively). Data are mean ± SEM of three or more independent experiments.

Journal: Journal of Molecular Endocrinology

Article Title: Syndecans modulate ghrelin receptor signaling

doi: 10.1530/JME-24-0070

Figure Lengend Snippet: Syndecans (SDCs) enhance ghrelin-stimulated growth hormone secretagogue receptor (GHSR) signaling. (A) Time course of aequorin luminescence after ghrelin treatment in cells expressing GHSR with control or SDC1 expression plasmids at 1:20 ratio. (B) Comparison of peak iCa 2+ responses derived from curve-fitting data from A (* P < 0.05, GHSR alone versus SDC1 co-transfection). (C) Dose–response curves of intracellular ghrelin-stimulated iCa 2+ expressed as % Emax of 1:0 ratio: effect of different GHSR:SDC1 transfection ratios (* P < 0.05, *** P < 0.0005, Emax for GHSR:SDC co-expression versus GHSR alone (GHSR:SDC, 1:0) tested by ANOVA). (D) EC 50 s for ghrelin derived from dose–response curves shown in (C) (SDC1 ratios). (E) Effect of all SDCs co-transfected at a GHSR:SDC ratio of 1:20 (** P < 0.005 (t-test), Emax for GHSR:SDC co-expression versus GHSR alone). (F) Effect of all SDCs co-transfected at a GHSR:SDC ratio of 1:1 (* P ≤ 0.05 (t-test), Emax for GHSR:SDC co-expression versus GHSR alone). (G) EC 50 s for ghrelin derived from SDC1–SDC4 dose–response curves shown in (E) and (F). (H) and (I) Dose–response curves of IP1 accumulation after ghrelin stimulation of cells expressing GHSR in the presence or absence of SDC1 at 1:20 and 1:1 ratios, respectively, corrected for baseline (* P ≤ 0.05 (t-test), Emax ghrelin-induced IP1 levels of 1:0 v. 1:20 or 1:1 ratio). (J) and (K) Dose–response curves of IP1 levels after ghrelin stimulation of cells expressing GHSR in the presence or absence of SDC1 at 1:20 and 1:1 ratios, respectively, expressed as % of maximum response in the absence of SDC1 (* P ≤ 0.05, ** P < 0.01 (t-test), basal IP1 levels of 1:0 v. 1:20 or 1:1 ratio, respectively). Data are mean ± SEM of three or more independent experiments.

Article Snippet: pCMV3 vectors containing cDNAs for human SDC1 (NM_001006946.1), SDC2 (NM_002998.3), SDC4 (NM_002999.2) and negative control were obtained from SinoBiological (Germany).

Techniques: Expressing, Control, Comparison, Derivative Assay, Cotransfection, Transfection

Syndecans (SDCs) reduce plasma membrane growth hormone secretagogue receptor (GHSR) availability. Plasma membrane (extracellular) expression of GHSR-HiBiT. (A) Effect of increasing GHSR:SDC1 expression plasmid ratios on cell surface levels expressed as % luminescence intensity relative to control (1:0 ratio). (B) Effect of all SDCs (GHSR:SDC, 1:20) expressed as % luminescence intensity relative to control (1:0 ratio). (C) Effect of all SDCs (GHSR:SDC, 1:1) expressed as % luminescence intensity relative to control (1:0 ratio). (D) Effect of MRAP2 on ghrelin-induced GHSR internalization using HiBiT. (E) Bystander BRET evaluation of effect of all SDCs on cell surface levels of GHSR expressed as netBRET % of 1:0 control (GHSR:SDC ratios of 1:0 to 1:20; * P < 0.05, *** P < 0.005 versus 1:0). (F) Effect of MRAP2 on ghrelin-induced GHSR internalization using bystander BRET. (G) Effect of SDCs on total GHSR expression assessed by measuring GHSR-NLuc derived luminescence of bystander BRET assays (** P < 0.01). (H) Effect of SDCs at a GHSR:SDC ratio of 1:20 on 1 μM ghrelin-induced internalization using the HiBiT assay. (I) Percentage internalization 50 min following ghrelin treatment relative to vehicle from (H). (J) Effect of SDCs at a GHSR:SDC ratio of 1:1 on 1 μM ghrelin-induced internalization using the HiBiT assay. (K) Percentage internalization 50 min following ghrelin treatment relative to vehicle from (J). Data are corrected for baseline and then expressed as % of vehicle controls at each time point. Data are presented as mean ± SEM of 3–7 independent experiments. Letters a–d represent groups that are significantly different from each other ( P < 0.05; one-way ANOVA).

Journal: Journal of Molecular Endocrinology

Article Title: Syndecans modulate ghrelin receptor signaling

doi: 10.1530/JME-24-0070

Figure Lengend Snippet: Syndecans (SDCs) reduce plasma membrane growth hormone secretagogue receptor (GHSR) availability. Plasma membrane (extracellular) expression of GHSR-HiBiT. (A) Effect of increasing GHSR:SDC1 expression plasmid ratios on cell surface levels expressed as % luminescence intensity relative to control (1:0 ratio). (B) Effect of all SDCs (GHSR:SDC, 1:20) expressed as % luminescence intensity relative to control (1:0 ratio). (C) Effect of all SDCs (GHSR:SDC, 1:1) expressed as % luminescence intensity relative to control (1:0 ratio). (D) Effect of MRAP2 on ghrelin-induced GHSR internalization using HiBiT. (E) Bystander BRET evaluation of effect of all SDCs on cell surface levels of GHSR expressed as netBRET % of 1:0 control (GHSR:SDC ratios of 1:0 to 1:20; * P < 0.05, *** P < 0.005 versus 1:0). (F) Effect of MRAP2 on ghrelin-induced GHSR internalization using bystander BRET. (G) Effect of SDCs on total GHSR expression assessed by measuring GHSR-NLuc derived luminescence of bystander BRET assays (** P < 0.01). (H) Effect of SDCs at a GHSR:SDC ratio of 1:20 on 1 μM ghrelin-induced internalization using the HiBiT assay. (I) Percentage internalization 50 min following ghrelin treatment relative to vehicle from (H). (J) Effect of SDCs at a GHSR:SDC ratio of 1:1 on 1 μM ghrelin-induced internalization using the HiBiT assay. (K) Percentage internalization 50 min following ghrelin treatment relative to vehicle from (J). Data are corrected for baseline and then expressed as % of vehicle controls at each time point. Data are presented as mean ± SEM of 3–7 independent experiments. Letters a–d represent groups that are significantly different from each other ( P < 0.05; one-way ANOVA).

Article Snippet: pCMV3 vectors containing cDNAs for human SDC1 (NM_001006946.1), SDC2 (NM_002998.3), SDC4 (NM_002999.2) and negative control were obtained from SinoBiological (Germany).

Techniques: Membrane, Expressing, Plasmid Preparation, Control, Derivative Assay

Syndecans (SDCs) require growth hormone secretagogue receptor (GHSR) and Gα q/11 to enhance ghrelin-induced signaling but do not potentiate activation of Gq directly. (A) Effect of SDC1 on ghrelin-stimulated intracellular calcium levels in cells with or without GHSR expression. (B) Effect of SDC1 on ghrelin-stimulated Ca 2+ release in GNAQ/11 WT (inset) and KO HEK293 cells (*** P < 0.0005 versus own control. WT, wild-type parental cell-line; KO, GNAQ/11 knockout. Data are corrected for WT control Emax). (C) Lack of effect of different GHSR:SDC1 ratios on ligand-independent Gα q biosensor activity. (D) Lack of effect of different GHSR:SDC1 ratios on ghrelin-stimulated Gα q activation, as measured by a decrease in BRET over the prestimulation baseline. (E) Kinetics of the Gq-CASE response during the first 60 s following ghrelin treatment, showing 1:0 (control), 1:1 and 1:10 GHSR:SDC1 ratios (SEM represented by the dotted lines). (F) and (G) Maximal response and half-times derived from curve-fitting of data shown in (E) (ANOVA gave no significant differences). For all experiments, data are presented as mean ± SEM of 3–4 independent experiments.

Journal: Journal of Molecular Endocrinology

Article Title: Syndecans modulate ghrelin receptor signaling

doi: 10.1530/JME-24-0070

Figure Lengend Snippet: Syndecans (SDCs) require growth hormone secretagogue receptor (GHSR) and Gα q/11 to enhance ghrelin-induced signaling but do not potentiate activation of Gq directly. (A) Effect of SDC1 on ghrelin-stimulated intracellular calcium levels in cells with or without GHSR expression. (B) Effect of SDC1 on ghrelin-stimulated Ca 2+ release in GNAQ/11 WT (inset) and KO HEK293 cells (*** P < 0.0005 versus own control. WT, wild-type parental cell-line; KO, GNAQ/11 knockout. Data are corrected for WT control Emax). (C) Lack of effect of different GHSR:SDC1 ratios on ligand-independent Gα q biosensor activity. (D) Lack of effect of different GHSR:SDC1 ratios on ghrelin-stimulated Gα q activation, as measured by a decrease in BRET over the prestimulation baseline. (E) Kinetics of the Gq-CASE response during the first 60 s following ghrelin treatment, showing 1:0 (control), 1:1 and 1:10 GHSR:SDC1 ratios (SEM represented by the dotted lines). (F) and (G) Maximal response and half-times derived from curve-fitting of data shown in (E) (ANOVA gave no significant differences). For all experiments, data are presented as mean ± SEM of 3–4 independent experiments.

Article Snippet: pCMV3 vectors containing cDNAs for human SDC1 (NM_001006946.1), SDC2 (NM_002998.3), SDC4 (NM_002999.2) and negative control were obtained from SinoBiological (Germany).

Techniques: Activation Assay, Expressing, Control, Knock-Out, Activity Assay, Derivative Assay

Syndecans (SDCs) impair β-arrestin2 recruitment at growth hormone secretagogue receptor (GHSR). (A) Effect of SDC1 on ghrelin-stimulated β-arrestin2–GHSR interaction in HEK293 cells. Values were corrected for Emax of the control (*** P < 0.0005 versus 1:0 ratio GHSR:SDC1; # P < 0.05, ## P < 0.005 versus 1:2 ratio GHSR:SDC1). (B) Effect of SDC1 on the kinetic profile of the β-arrestin2–GHSR interaction upon ghrelin stimulation (outcome of RM-ANOVA shown on graph: P T , effect of time; P Ratio , effect of GHSR:SDC ratio; P TxRatio , interaction. * P < 0.05, all other ratios versus 1:0 ratio GHSR:SDC1; # P < 0.05, 1:1 and 1:2 versus 1:0 ratio; $ P < 0.05, 1:2 versus 1:0 ratio). Data derived from curve fitting of the kinetic profiles for β-arrestin2 recruitment by GHSR in cells transfected with control or increasing amounts of SDC1 expression plasmid. (C) Initial rate of recruitment. (D) Magnitude of peak response (letters a and b represent groups that are significantly different from each other ( P < 0.05; one-way ANOVA). Dose–response curve (E) (*** P < 0.0005 versus control; # P < 0.05 versus 1:2 ratio GHSR:SDC1) and kinetic curve (F) of the effect of all SDCs (GHSR:SDC of 1:2) on β-arrestin2 recruitment at GHSR (outcome of RM-ANOVA shown on graph. * P < 0.05, *** P < 0.001, all SDCs versus control; # P < 0.05, SDC1, SDC2 and SDC4 versus control; $ P < 0.05, SDC2 and SDC4 versus control. P T , effect of time; P Ratio , effect of GHSR:SDC ratio; P TxRatio , interaction). Data derived from curve fitting of the kinetic profiles for β-arrestin2 recruitment by GHSR in cells transfected with control or SDC1, SDC2, SDC3 or SDC4 expression plasmids. (G) Initial rate of recruitment. (H) Magnitude of peak response (letters a and b represent groups that are significantly different from each other ( P < 0.05; one-way ANOVA). Data are presented as mean ± SEM of three independent experiments. Emax, maximum response.

Journal: Journal of Molecular Endocrinology

Article Title: Syndecans modulate ghrelin receptor signaling

doi: 10.1530/JME-24-0070

Figure Lengend Snippet: Syndecans (SDCs) impair β-arrestin2 recruitment at growth hormone secretagogue receptor (GHSR). (A) Effect of SDC1 on ghrelin-stimulated β-arrestin2–GHSR interaction in HEK293 cells. Values were corrected for Emax of the control (*** P < 0.0005 versus 1:0 ratio GHSR:SDC1; # P < 0.05, ## P < 0.005 versus 1:2 ratio GHSR:SDC1). (B) Effect of SDC1 on the kinetic profile of the β-arrestin2–GHSR interaction upon ghrelin stimulation (outcome of RM-ANOVA shown on graph: P T , effect of time; P Ratio , effect of GHSR:SDC ratio; P TxRatio , interaction. * P < 0.05, all other ratios versus 1:0 ratio GHSR:SDC1; # P < 0.05, 1:1 and 1:2 versus 1:0 ratio; $ P < 0.05, 1:2 versus 1:0 ratio). Data derived from curve fitting of the kinetic profiles for β-arrestin2 recruitment by GHSR in cells transfected with control or increasing amounts of SDC1 expression plasmid. (C) Initial rate of recruitment. (D) Magnitude of peak response (letters a and b represent groups that are significantly different from each other ( P < 0.05; one-way ANOVA). Dose–response curve (E) (*** P < 0.0005 versus control; # P < 0.05 versus 1:2 ratio GHSR:SDC1) and kinetic curve (F) of the effect of all SDCs (GHSR:SDC of 1:2) on β-arrestin2 recruitment at GHSR (outcome of RM-ANOVA shown on graph. * P < 0.05, *** P < 0.001, all SDCs versus control; # P < 0.05, SDC1, SDC2 and SDC4 versus control; $ P < 0.05, SDC2 and SDC4 versus control. P T , effect of time; P Ratio , effect of GHSR:SDC ratio; P TxRatio , interaction). Data derived from curve fitting of the kinetic profiles for β-arrestin2 recruitment by GHSR in cells transfected with control or SDC1, SDC2, SDC3 or SDC4 expression plasmids. (G) Initial rate of recruitment. (H) Magnitude of peak response (letters a and b represent groups that are significantly different from each other ( P < 0.05; one-way ANOVA). Data are presented as mean ± SEM of three independent experiments. Emax, maximum response.

Article Snippet: pCMV3 vectors containing cDNAs for human SDC1 (NM_001006946.1), SDC2 (NM_002998.3), SDC4 (NM_002999.2) and negative control were obtained from SinoBiological (Germany).

Techniques: Control, Derivative Assay, Transfection, Expressing, Plasmid Preparation

Teclistamab-induced cytotoxicity and activation of MM BM MNC cells ex vivo. Each row represents a different patient sample. Frozen BM MNCs were incubated with various concentrations of teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target binding and killing. BCMA protein density was 2451 receptors per plasma cell in one of the patient samples (ID BM 240 MM). (A) Dose-dependent binding of teclistamab to target cells. (B) Dose-dependent plasma cell depletion. BM MNCs were incubated for 48 hours with exogenous healthy T cells at a 1:1 E:T ratio in the presence of teclistamab and depletion measured as remaining CD138+ cells. (C) Teclistamab-mediated T-cell activation was measured via flow cytometry by gating T cells using CD3 surface marker and CD25 activation marker. Percent CD25+ T cell values were plotted on the y-axis. Teclistamab was able to activate T cells efficiently when incubated with BM MNCs, whereas the control antibodies had no effect.

Journal: Blood Advances

Article Title: Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

doi: 10.1182/bloodadvances.2020002393

Figure Lengend Snippet: Teclistamab-induced cytotoxicity and activation of MM BM MNC cells ex vivo. Each row represents a different patient sample. Frozen BM MNCs were incubated with various concentrations of teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target binding and killing. BCMA protein density was 2451 receptors per plasma cell in one of the patient samples (ID BM 240 MM). (A) Dose-dependent binding of teclistamab to target cells. (B) Dose-dependent plasma cell depletion. BM MNCs were incubated for 48 hours with exogenous healthy T cells at a 1:1 E:T ratio in the presence of teclistamab and depletion measured as remaining CD138+ cells. (C) Teclistamab-mediated T-cell activation was measured via flow cytometry by gating T cells using CD3 surface marker and CD25 activation marker. Percent CD25+ T cell values were plotted on the y-axis. Teclistamab was able to activate T cells efficiently when incubated with BM MNCs, whereas the control antibodies had no effect.

Article Snippet: T cell–mediated cytotoxicity and T-cell activation using CD138 + BM cells from patients and healthy donor T cells MM patient BM MNCs (ProteoGenex) and T cells were incubated with 100 ng/mL of interleukin (IL)-6 and teclistamab or control antibody for 48 hours.

Techniques: Activation Assay, Ex Vivo, Incubation, Binding Assay, Clinical Proteomics, Flow Cytometry, Marker, Control